Roger Williams’ Immunotherapy research program highlighted at biotech convention
The Immunotherapy program of the Roger Williams’ Cancer Center represented the state of Rhode Island at the 2018 BIO International Convention, which took place from June 1-7 in Boston. The program at Roger Williams, which focuses on immunotherapy for liver metastases, multiple myeloma, and sarcoma, was chosen by the state as it represents a valuable and promising component of the Rhode Island bio-tech industry.
At the conference, Steven C. Katz, MD, Director of the Office of Therapeutic Development, Prajna Guha, PhD, Ashley Moody, RN, and John Hardaway, MD, PhD, met with academic and industry leaders to highlight the cutting edge immunotherapy clinical trials and world-class cGMP CAR-T manufacturing facility at Roger Williams. The conference also gave the team an opportunity to promote the recently-opened CAR-T trial for multiple myeloma led by Dr. Todd Roberts, upcoming CAR-T trial for peritoneal cancer, and upcoming phase 2 trial for metastatic liver tumors.
Pictured at the conference (from left to right) are first year surgical oncology fellow Dr. Hardaway, head immunotherapy nurse Ashley Moody, BSN, RN, and Dr. Katz. The conference is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.